Last reviewed · How we verify
A Study of Apatinib Combined With Letrozole With or Without Fluzoparib in Estrogen Receptor-Positive, Platinum-Sensitive Recurrent Ovarian Cancer Previously Treated With First-Line PARP Inhibitor
This multicenter, open-label, prospective cohort clinical study enrolled 70 patients with late-stage ER（+）platinum-sensitive recurrent ovarian cancer who had achieved CR/PR after first-line PARP inhibitor maintenance therapy. The study was divided into two cohorts, with 35 participants in each. Cohort 1 (triple-drug group) received the following treatments: Apatinib: 250 mg orally once daily, with a 28-day treatment cycle. Fluzoparib: 100 mg orally twice daily, with a 4-week continuous treatment cycle. Letrozole: 2.5 mg orally once daily, with a 4-week continuous treatment cycle. Cohort 2 (dual-drug group) received: Apatinib: 250 mg orally once daily, with a 28-day treatment cycle. Letrozole: 2.5 mg orally once daily, with a 4-week continuous treatment cycle. reatment continued until disease progression, intolerable toxicity, or other protocol-specified reasons occurred.
Details
| Lead sponsor | Peking Union Medical College Hospital |
|---|---|
| Phase | NA |
| Status | TERMINATED |
| Enrolment | 5 |
| Start date | Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Mon Mar 30 2026 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Ovarian Cancer
Interventions
- Cohort 1 (triple-drug group)
- Cohort 2 (dual-drug group)
Countries
China